Application of CoMFA and CoMSIA 3D-QSAR and Docking Studies in Optimization of Mercaptobenzenesulfonamides as HIV-1 Integrase Inhibitors

Journal of Medicinal Chemistry

Volumn 47, Issue 2, 2004, Pages 385-399

  Kuo, Chih Ling ^a   Assefa, Haregewein ^b   Kamath, Shantaram ^b   Brzozowski, Zdzialaw ^c   Slawinski, Jaroslaw ^c   Saczewski, Franciszek ^c   Buolamwini, John K ^b   Neamati, Nouri ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

2 MERCAPTOBENZENESULFONAMIDE DERIVATIVE; INTEGRASE; INTEGRASE INHIBITOR; MERCAPTOBENZENESULFONAMIDE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE; SULFONAMIDE; UNCLASSIFIED DRUG;

ARTICLE; COMPARATIVE MOLECULAR FIELD ANALYSIS; COMPARATIVE MOLECULAR SIMILARITY INDICES ANALYSIS; DNA TRANSFER; DRUG DESIGN; HUMAN IMMUNODEFICIENCY VIRUS; QUANTITATIVE STRUCTURE ACTIVITY RELATION; RELIABILITY; SCORING SYSTEM; VALIDATION PROCESS; VIRUS INHIBITION; VIRUS REPLICATION;

HIV INTEGRASE; HIV INTEGRASE INHIBITORS; HIV-1; MODELS, MOLECULAR; PROTEIN BINDING; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; SULFHYDRYL COMPOUNDS; SULFONAMIDES;

EID: 0347593982     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm030378i     Document Type: Article

References (35)

1. Brown, P. O. Integration; Cold Spring Harbor Press: Cold Spring Harbor, NY, 1999.
2. Asante-Appiah, E.; Skalka, A. M. HIV-1 integrase: structural organization, conformational changes, and catalysis. Adv. Virus Res. 1999, 52, 351-369.
3. Neamati, N. Patented small molecule inhibitors of HIV-1 integrase: a ten-year saga. Expert Opin. Ther. Pat. 2002, 12, 709-724.
4. Dayam, R.; Neamati, N. Small-Molecule HIV-1 Integrase Inhibitors: the 2001-2002 Update. Curr. Pharm. Des. 2003, 9, 1789-1802.
5. Neamati, N.; Barchi, J. J., Jr. New paradigms in drug design and discovery. Curr. Top. Med. Chem. 2002, 2, 211-227.
6. Neamati, N.; Mazumder, A.; Sunder, S.; Owen, J. M.; Schultz, R. J.; Pommier, Y. 2-Mercaptobenzenesulfonamides as novel class of human immunodeficiency type 1 (HIV-1) integrase and HIV-1 replication. Antimicrob. Agents Chemother. 1997, 8, 485-495.
7. Nicklaus, M. C.; Neamati, N.; Hong, H.; Mazumder, A.; Sunder, S.; Chen, J.; Milne, G. W.; Pommier, Y. HIV-1 integrase pharmacophore: discovery of inhibitors through three-dimensional database searching. J. Med. Chem. 1997, 40, 920-929.
8. Lubkowski, J.; Yang, F.; Alexandratos, J.; Wlodawer, A.; Zhao, H.; Burke, T. R., Jr.; Neamati, N.; Pommier, Y.; Merkel, G.; Skalka, A. M. Structure of the catalytic domain of avian sarcoma virus integrase with a bound HIV-1 integrase-targeted inhibitor. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 4831-4836.
9. Neamati, N.; Mazumder, A.; Zhao, H.; Sunder, S.; Burke, T. R., Jr.; Schultz, R. J.; Pommier, Y. Diarylsulfones, a novel class of human immunodeficiency virus type 1 integrase inhibitors. Antimicrob. Agents Chemother. 1997, 41, 385-393.
10. Chen, I. J.; Neamati, N.; Nicklaus, M. C.; Orr, A.; Anderson, L.; Barchi, J. J., Jr.; Kelley, J. A.; Pommier, Y.; MacKerell, A. D., Jr. Identification of HIV-1 integrase inhibitors via three-dimensional database searching using ASV and HIV-1 integrases as targets. Bioorg. Med. Chem. 2000, 8, 2385-2398.
11. Neamati, N.; Lin, Z.; Karki, R. G.; Orr, A.; Cowansage, K.; Strumberg, D.; Pais, G. C.; Voigt, J. H.; Nicklaus, M. C.; Winslow, H. E.; Zhao, H.; Turpin, J. A.; Yi, J.; Skalka, A. M.; Burke, T. R., Jr.; Pommier, Y. Metal-dependent inhibition of HIV-1 integrase. J. Med. Chem. 2002, 45, 5661-5670.
12. Pannecouque, C.; Pluymers, W.; Van Maele, B.; Tetz, V.; Cherepanov, P.; De Clercq, E.; Witvrouw, M.; Debyser, Z. New class of HIV integrase inhibitors that block viral replication in cell culture. Curr. Biol. 2002, 12, 1169-1177.
13. Scozzafava, A.; Owa, T.; Mastrolorenzo, A.; Supuran, C. T. Anticancer and antiviral sulfonamides. Curr. Med. Chem. 2003, 10, 925-953.
14. Brzozowski, Z. 2-Mercapto-N-(azolyl)benzenesulphonamides. I. Synthesis of N-(1,1-dioxo-1,4,2-benzodithiazin-3-yl)guanidines and their transformations into 2-mercapto-N-(5-amino-1,2,4-triazol-3-yl) benzenesulphonamide derivatives with potential anti-HIV or anticancer activity. Acta Pol. Pharm. 1995, 52, 91-101.
15. Brzozowski, Z. 2-Mercapto-N-(azolyl)benzenesulphonamides. II. Syntheses, anti-HIV-1 and anticancer activity of some S-substituted 4-chloro-2-mercapto-5-methyl-N-(5-amino-1,2,4-triazol-3-yl) benzenesulphonamides. Acta Pol Pharm. 1995, 52, 287-292.
16. Brzozowski, Z. 2-mercapto N-(azolyl)benzenesulfonamides. VI. Synthesis and anti-HIV activity of some new 2-mercapto-N-(1,2,4-triazol-3-yl)benzenesulfonamide derivatives containing the 1,2,4-triazole moiety fused with a variety of heteroaromatic rings. Acta Pol. Pharm. 1998, 55, 473-480.
17. Hazuda, D. J.; Felock, P.; Witmer, M.; Wolfe, A.; Stillmock, K.; Grobler, J. A.; Espeseth, A.; Gabryelski, L.; Schleif, W.; Blau, C.; Miller, M. D. Inhibitors of strand transfer that prevent integration and inhibit HI-1 replication in cells. Science. 2000, 287, 646-650.
18. Pais, G. C. G.; Burke, T. R. Novel aryl diketo-containing inhibitors of HIV-1 integrase. Drugs Future 2002, 27, 1101-1111.
19. Wold, S.; Rhue, A.; Wold, H.; Dunn, W. J. I. The covariance problem in linear regression. The partial least squares (PLS) approach to generalized inverses. SAIM J. Sci. Stat. Comput. 1994, 5, 735-743.
20. Wold, S.; Albano, C.; Dunn, W. J., III; Edlund, U.; Esbensen, K.; Geladi, P.; Hellberg, S.; Johanson, E.; Lindberg, W.; Sjostrom, M. Multivariate data analysis in chemistry. NATO ASI Ser., Ser. C 1984, 138, 17-95.
21. Clark, M.; Cramer, I., R. D. The probability of chance correlation using partial least squares (PLS). Quant. Struct-Act Relat. 1993, 12, 137-145.
22. Brzozowski, Z.; Saczewski, F.; Kuo, C.-L.; Sanchez, T.; Gdaniec, M.; Neamati, N., 2003, unpublished data.
23. Brzozowski, Z.; Slawinski, J.; Angielski, S.; Szczepanska-Konkiel, M. [Derivatives of 1,1-dioxo-1,4,2-benzodithiazine. III. Synthesis and diuretic properties of 3-(R,R1-phenyl)amino-6-chloro-7-methyl-1,1-dioxo-1,4,2-benzodithiazines]. Acta Pol. Pharm. 1985, 42, 313-318.
24. Brzozowski, Z. Syntheses of some new 4-chloro-2-mercapto-N-(4H-1,2,4-triazol-3-yl)benzenesulfonamides with potential anti-cancer or anti-HIV activity. Acta Pol. Pharm. 1997, 54, 461-466.
25. Slawinski, J. Synthesis, anti-HIV and anticancer activity of some S-substituted 4-chloro-2-mercapto-5-methyl-N-(5-amino-1,2,4-triazol-3-yl)benzenesulfonamides. Acta Pol. Pharm. 1995, 52, 287-292.
26. Brzozowski, Z. Synthesis of N-(1,1-dioxo-1,4,2-benzodithiazin-3-yl)guanidines and their transformation into 2-mercapto-N-(5-amino-1,2,4-triazol-3-yl)benzenesulfonamide derivatives with potential anti-HIV or anticancer activity. Acta Pol. Pharm. 1998, 55, 91-101.
27. Brzozowski, Z. Synthesis and anti-HIV activity of some new 2-mercato-N-(1,2,4-triazol-3-yl)benzenesulfonamide derivatives containing the 1,2,4-triazole moiety fused with a variety of heteroaromatic rings. Acta Pol. Pharm. 1998, 55, 473-480.
28. Brzozowski, Z.; Saczewski, F.; Gdaniec, M. Synthesis, structural characterization and in vitro anticancer activity of 4-dimethyl-aminopyridinium (6-chloro-1,1-dioxo-1,4,2-benzodithiazin-3-yl)-methanides. Bioorg Med Chem. 2003, in press.
29. SYBYL Version 6.7; Tripos Associates: St. Louis, MO.
30. Stewart, J. J. MOPAC: a semiempirical molecular orbital program. J. Comput.-Aided Mol. Des. 1990, 4, 1-105.
31. Klebe, G.; Abraham, U.; Mietzner, T. Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. J. Med. Chem. 1994, 37, 4130-4146.
32. Viswanadhan, V. N.; Ghose, A. K.; Revenkar, G. R.; Robins, R. Atomic and physichochemical parameters for three-dimensional structure-directed quantitative structure-activity relationships. 4. additional parameters for hydrophobic and dispersive interactions and their application for an automated superposition of certain naturally occurring antibiotics. J. Chem. Inf. Comput. Sci. 1989, 29, 163-172.
33. Klebe, G. The use of composite crystal-field environments in molecular recognition and the de novo design of protein ligands. J. Mol. Biol. 1994, 237, 212-235.
34. Kramer, B.; Rarey, M.; Lengauer, T. Evaluation of the FLEXX incremental construction algorithm for protein-ligand docking. Proteins 1999, 37, 228-241.
35. Rarey, M.; Kramer, B.; Lengauer, T.; Klebe, G. A fast flexible docking method using an incremental construction algorithm. J. Mol. Biol. 1996, 261, 470-489.